Michael E Reznik1, J Michael Schmidt1, Ali Mahta1, Sachin Agarwal1, David J Roh1, Soojin Park1, Hans Peter Frey1, Jan Claassen2. 1. Department of Critical Care Neurology, Columbia University Medical Center, 177 Fort Washington Avenue, Milstein Hospital Building, Suite 8-300, New York, NY, 10032, USA. 2. Department of Critical Care Neurology, Columbia University Medical Center, 177 Fort Washington Avenue, Milstein Hospital Building, Suite 8-300, New York, NY, 10032, USA. jc1439@cumc.columbia.edu.
Abstract
BACKGROUND: Agitated delirium is frequent following acute brain injury, but data are limited in patients with subarachnoid hemorrhage (SAH). We examined incidence, risk factors, and consequences of agitation in these patients in a single-center retrospective study. METHODS: We identified all patients treated with antipsychotics or dexmedetomidine from a prospective observational cohort of patients with spontaneous SAH. Agitation was confirmed by chart review. Outcomes were assessed at 12 months using the modified Rankin Scale (mRS), Telephone Interview for Cognitive Status (TICS), and Lawton IADL (Instrumental Activities of Daily Living) scores. Independent predictors were identified using logistic regression. RESULTS: From 309 SAH patients admitted between January 2011 and December 2015, 52 (17 %) developed agitation, frequently in the first 72 h (50 %) and in patients with Hunt-Hess grades 3-4 (12 % of grades 1-2, 28 % of grades 3-4, 8 % of grade 5). There was also a significant association between agitation and a history of cocaine use or prior psychiatric diagnosis. Agitated patients were more likely to develop multiple hospital complications; and in half of these patients, complications were diagnosed within 24 h of agitation onset. Agitation was associated with IADL impairment at 12 months (Lawton >8; p = 0.03, OR 2.7, 95 % CI, 1.1-6.8) in non-comatose patients (Hunt-Hess 1-4), but not with functional outcome (mRS >3), cognitive impairment (TICS ≤30), or ICU/hospital length of stay after controlling for other predictors. CONCLUSION: Agitation occurs frequently after SAH, especially in non-comatose patients with higher clinical grades. It is associated with the development of multiple hospital complications and may have an independent impact on long-term outcomes.
BACKGROUND:Agitated delirium is frequent following acute brain injury, but data are limited in patients with subarachnoid hemorrhage (SAH). We examined incidence, risk factors, and consequences of agitation in these patients in a single-center retrospective study. METHODS: We identified all patients treated with antipsychotics or dexmedetomidine from a prospective observational cohort of patients with spontaneous SAH. Agitation was confirmed by chart review. Outcomes were assessed at 12 months using the modified Rankin Scale (mRS), Telephone Interview for Cognitive Status (TICS), and Lawton IADL (Instrumental Activities of Daily Living) scores. Independent predictors were identified using logistic regression. RESULTS: From 309 SAHpatients admitted between January 2011 and December 2015, 52 (17 %) developed agitation, frequently in the first 72 h (50 %) and in patients with Hunt-Hess grades 3-4 (12 % of grades 1-2, 28 % of grades 3-4, 8 % of grade 5). There was also a significant association between agitation and a history of cocaine use or prior psychiatric diagnosis. Agitatedpatients were more likely to develop multiple hospital complications; and in half of these patients, complications were diagnosed within 24 h of agitation onset. Agitation was associated with IADL impairment at 12 months (Lawton >8; p = 0.03, OR 2.7, 95 % CI, 1.1-6.8) in non-comatosepatients (Hunt-Hess 1-4), but not with functional outcome (mRS >3), cognitive impairment (TICS ≤30), or ICU/hospital length of stay after controlling for other predictors. CONCLUSION:Agitation occurs frequently after SAH, especially in non-comatosepatients with higher clinical grades. It is associated with the development of multiple hospital complications and may have an independent impact on long-term outcomes.
Authors: Timothy D Girard; James C Jackson; Pratik P Pandharipande; Brenda T Pun; Jennifer L Thompson; Ayumi K Shintani; Sharon M Gordon; Angelo E Canonico; Robert S Dittus; Gordon R Bernard; E Wesley Ely Journal: Crit Care Med Date: 2010-07 Impact factor: 7.598
Authors: S A Mayer; K T Kreiter; D Copeland; G L Bernardini; J E Bates; S Peery; J Claassen; Y E Du; E S Connolly Journal: Neurology Date: 2002-12-10 Impact factor: 9.910
Authors: Marielle W A van Rijsbergen; Annemarie W Oldenbeuving; Ruth E Nieuwenhuis-Mark; Gudrun M S Nys; Sylvia G M Las; Gerwin Roks; Paul L M de Kort Journal: J Neurol Sci Date: 2011-04-09 Impact factor: 3.181
Authors: Yahya Shehabi; Richard R Riker; Paula M Bokesch; Wayne Wisemandle; Ayumi Shintani; E Wesley Ely Journal: Crit Care Med Date: 2010-12 Impact factor: 7.598
Authors: Michael C Reade; Glenn M Eastwood; Rinaldo Bellomo; Michael Bailey; Andrew Bersten; Benjamin Cheung; Andrew Davies; Anthony Delaney; Angaj Ghosh; Frank van Haren; Nerina Harley; David Knight; Shay McGuiness; John Mulder; Steve O'Donoghue; Nicholas Simpson; Paul Young Journal: JAMA Date: 2016-04-12 Impact factor: 56.272
Authors: Michael E Reznik; Ali Mahta; J Michael Schmidt; Hans-Peter Frey; Soojin Park; David J Roh; Sachin Agarwal; Jan Claassen Journal: Neurocrit Care Date: 2018-08 Impact factor: 3.210
Authors: David Robinson; Stephanie Thompson; Andrew Bauerschmidt; Kara Melmed; Caroline Couch; Soojin Park; Sachin Agarwal; David Roh; E Sander Connolly; Jan Claassen Journal: Neurocrit Care Date: 2019-06 Impact factor: 3.210